Temozolomide and Paclitaxel for Advanced Melanoma
Author Information
Author(s): Azzabi A, Hughes A N, Calvert P M, Plummer E R, Todd R, Griffin M J, Lind M J, Maraveyas A, Kelly C, Fishwick K, Calvert A H, Boddy A V
Primary Institution: Northern Institute for Cancer Research, University of Newcastle
Hypothesis
The study aims to determine the activity of temozolomide combined with paclitaxel in patients with advanced malignant melanoma.
Conclusion
The combination of temozolomide and paclitaxel can be administered safely at clinically effective doses, showing some activity in treating advanced melanoma.
Supporting Evidence
- Temozolomide and paclitaxel were both active against melanoma cell lines.
- Two partial responses were observed in the clinical study.
- No dose-limiting toxicities were observed at the highest doses tested.
- Pharmacokinetics showed no interaction between temozolomide and paclitaxel.
Takeaway
Doctors tested a new medicine combination to help people with a serious skin cancer, and it seemed to work without making them too sick.
Methodology
The study involved in vitro tests on melanoma cell lines and a Phase I clinical trial with dose escalation of temozolomide and paclitaxel in patients.
Limitations
The study had a small sample size and was limited to a Phase I trial, which primarily focused on safety rather than efficacy.
Participant Demographics
22 patients (13 male, 9 female) with a median age of 52.5 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website